Gilead hepatitis C drug proves itself in key study

Thu Apr 19, 2012 4:03pm IST

Related Topics

Stocks

   

(Reuters) - An experimental hepatitis C drug acquired by Gilead Sciences Inc when it paid nearly $11 billion to buy Pharmasset has produced encouraging results in a closely-watched clinical trial, results of which were released in Barcelona.

The U.S. company said that of 25 patients with genotype 1 hepatitis who completed 12 weeks of treatment with a combination of GS-7977 and the older antiviral ribavirin (RBV), 88 percent still had undetectable levels of virus four weeks after completion of treatment.

Three patients in the study, known as ELECTRON, experienced viral relapse.

A second study, QUANTUM, which contained more difficult to treat patients, produced less impressive results, with 59 percent of patients having undetectable virus levels.

Mark Schoenebaum, an analyst at ISI Group, said the ELECTRON data was better than expected, since most analysts had expected a result around 50 percent, while the QUANTUM result was about in-line with expectations.

The market for treating hepatitis C has burgeoned in the last year with two new breakthrough treatments approved for sale in the United States and the promise of even better medicines in the pipeline, like the Gilead drug GS-7977.

GS-7977 works by blocking an enzyme essential to the replication of the hepatitis C virus. It is one of a new class of treatments designed to be given without interferon, which helps boost the body's immune system but can also cause debilitating, flu-like symptoms.

Vertex Pharmaceuticals Inc's new hepatitis C drug Incivek and Merck & Co's Victrelis both won U.S. approval last year.

(Reporting by Ben Hirschler; Editing by Mark Potter)

FILED UNDER:

Reuters Showcase

India Crush UAE

India Crush UAE

India cruise to easy win over UAE in Perth.  Read 

Budget 2015

Budget 2015

Full coverage of 2015/16 budget.  Full Coverage 

Sahara Saga

Sahara Saga

Some staff say Sahara has not paid salaries for months   Full Article 

Movie Review

Movie Review

"Dum Laga Ke Haisha" is rooted in reality, writes Shilpa Jamkhandikar.  Full Article | Related Story 

Nimoy Dies

Nimoy Dies

Leonard Nimoy, Star Trek's 'Mr. Spock,' dies at 83.  Full Article 

Gown Returned

Gown Returned

Lupita Nyong'o's $150,000 Oscar gown returned by thief via TMZ.  Full Article 

World Cup 2015

World Cup 2015

Full coverage of cricket world cup in Australia and New Zealand.  Full Coverage 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device.  Full Coverage